TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05078398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POINT Protocol
Description: Patients will receive counseling on risks and benefits of opioids for pain control, asked to choose whether they need opioid prescription when ready for discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Will prescribe standardized amount of opioid for postoperative pain without patient input
Study: NCT06562972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal equilibration of complete denture using articulating paper
Description: Occlusal equilibration of complete dentures is vital for ensuring proper function, comfort, and longevity. The process aims to evenly distribute occlusal forces, eliminate premature contacts, improve stability, reduce wear, and minimize tissue trauma. It involves methods like the articulating paper technique, pressure indicator paste, T-Scan digital analysis, and clinical observation. The process includes evaluating centric and eccentric contacts, making fine adjustments, and achieving balanced articulation. Regular follow-ups are essential to monitor occlusion and make necessary adjustments, contributing to patient satisfaction and denture lifespan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occlusal equilibration of complete denture using occulosense
Description: Occulosense denture equilibration is a digital occlusal analysis technique used to optimize denture fit and function. It employs a thin sensor placed between the dentures to measure bite force and timing. The system provides real-time data on occlusal contacts, allowing dentists to identify and adjust pressure points precisely. This process ensures even distribution of bite forces, enhancing denture stability, comfort, and longevity. T-Scan equilibration can significantly improve patient satisfaction by reducing pain, increasing chewing efficiency, and minimizing denture-related issues like sore spots and uneven wear.
Study: NCT06072755

Intervention type: DEVICE
Intervention: Finger pulse oximetry probe
Description: This finger probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.

Intervention type: DEVICE
Intervention: Transreflectance oximetry probe
Description: This neck probe will be used to make noninvasive measurements of systemic arterial and central venous oxygen saturations.
Study: NCT05366153

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT
Description: Screening/Management Plan

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT
Description: Screening/Management Plan
Study: NCT05742061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: PRP preparation :- 20 ml of venous blood will be drawn from the antecubital vein using an 18G needle to avoid traumatizing platelets and will be collected in a sterile tube containing 2 ml of Sodium Citrate anticoagulant. Approximately 2 ml of whole blood will be separated for a complete blood count.The blood with anticoagulant will centrifuged at 4000 rpm for 6-10 minutes to separate erythrocytes and then at 4000 rpm for 6-10 min to concentrate platelets.The final product was 4-5 ml of PRP containing leukocytes with platelet concentration of 3-5 times the average normal value.
Study: NCT06155149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Family Information Training
Description: Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Information Training
Description: Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
Study: NCT05531838

Intervention type: DEVICE
Group type: OTHER
Intervention: Fu Lishan instant sense hospital dynamic glucose monitoring system
Description: Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
Study: NCT05775146

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation treatment (SBRT)
Description: SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
Study: NCT05951231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver transplantation
Description: Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
Study: NCT06389565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy
Description: Problem solving therapy (PST) is a cognitive-behavioral therapy (CBT)-based intervention that uses seven basic steps to teach problem solving orientation and skills to equip individuals to manage the impact of stressful life events on their mental health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem solving therapy (PST) is a cognitive-behavioral therapy (CBT)-based intervention that uses seven basic steps to teach problem solving orientation and skills to equip individuals to manage the impact of stressful life events on their mental health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change My Story
Description: Change My Story is a narrative game with a choose-your-own-adventure format in which players navigate emotionally difficult experiences along with the character(s) and interact with the virtual environment to choose a narrative path toward the story's conclusion. It will used to address important obstacles in the mental health treatment gap for Y-PLWH.
Study: NCT05987267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary precision care
Description: The experimental group received precision nursing based on a multidisciplinary collaborative team in addition to standard treatment and care
Study: NCT05128487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-101150
Description: NDI-101150 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-101150
Description: NDI-101150 capsules
Study: NCT04975373

Intervention type: DRUG
Group type: OTHER
Intervention: Intrauterine injection of hyaluronic acid
Description: operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
Study: NCT05128487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion
Study: NCT05480384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Given in combination with Nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Given in combination with Nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Given in combination with Nivolumab.
Study: NCT06152341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATC System
Description: The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
Study: NCT06576167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPROVE
Description: IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPROVE
Description: IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPROVE
Description: IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
Study: NCT06435598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based health education
Description: The video- based health education program guided by the Health Belief Model will be designed to provide tailored information on insulin therapy in diabetes. Health Belief Model(HBM) emphasizes changes in people's behavior are acquired through awareness of risk factors and perceived health benefits. The video will provide general information on insulin, types of insulin, its administration technique and storage.
Study: NCT06263179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target Heartrate Aerobic Exercise
Description: Exercise program
Study: NCT05503797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral tablets
Study: NCT04065386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active taVNS
Description: Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham taVNS
Description: Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
Study: NCT05224141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo
Description: Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study: NCT06583538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giraffe Healthcare
Description: An online personalised rehabilitation platform consisting of exercise videos with written and audio instruction, an exercise diary, advice and in-built messaging system between therapist and participant.~The exercise prescription consists of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks
Study: NCT06246513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRP-9003
Description: Solution for single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Oral tablet (prophylactic)
Study: NCT05246111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Berzosertib
Description: Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Study: NCT05452642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Description: Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
Study: NCT04983823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)
Description: A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: This will be provided by participants' usual healthcare professional(s).
Study: NCT04976335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Versawrap membrane
Description: Versawrap membrane will be placed between distal radius plate and flexor tendons
Study: NCT04323449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compare two control methods for a wheelchair-mounted robotic manipulator
Description: Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compare two control methods for a wheelchair-mounted robotic manipulator
Description: Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
Study: NCT06562712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Patients will be subjected to conventional management for placenta accreta spectrum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral internal iliac artery balloon occlusion
Description: Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
Study: NCT06562530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone power therapy
Description: sessions are applied for 30 minutes, 3 times per week, for 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS)
Description: sessions are applied for 30 minutes, 3 times per week, for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
Study: NCT05515627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
Study: NCT05855525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience sampling
Description: Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
Study: NCT06568653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exosome
Description: human placenta mesenchymal stem cell-derived exosome

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine conventional fistulotomy
Description: routine conventional fistulotomy
Study: NCT05649852

Intervention type: OTHER
Group type: OTHER
Intervention: Socio-aesthetic care
Description: Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.